| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/S41409-020-01088-7 |
| P698 | PubMed publication ID | 33077902 |
| P50 | author | Yongxian Hu | Q99564972 |
| Yi Luo | Q100737195 | ||
| He Huang | Q64098079 | ||
| P2093 | author name string | Yang Yang | |
| Jian Yu | |||
| Jimin Shi | |||
| Xiaoyu Lai | |||
| Yamin Tan | |||
| Yanmin Zhao | |||
| Luxin Yang | |||
| P2860 | cites work | Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation | Q89777621 |
| Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT | Q90182584 | ||
| Prophylactic donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation for high risk haematological malignancies: a retrospective bicentric analysis of serial infusions of increasing doses of CD3+ cells | Q91041909 | ||
| Donor lymphocyte infusion for prevention of relapse after unmanipulated haploidentical PBSCT for very high-risk hematologic malignancies | Q91134140 | ||
| The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China | Q91455442 | ||
| Outcomes and Prognostic Factors for Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation: A KSGCT Multicenter Analysis | Q92804390 | ||
| TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation | Q27853319 | ||
| Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose | Q30558271 | ||
| Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation | Q33405278 | ||
| HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation | Q33566388 | ||
| T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT | Q34398411 | ||
| Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation | Q35103562 | ||
| Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia | Q37072126 | ||
| Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease-Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory/Relapsed | Q38797132 | ||
| Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission | Q39002077 | ||
| Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Unrelated Allogeneic Bone Marrow Transplantation Facilitated by the Japan Marrow Donor Program | Q40324842 | ||
| Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation. | Q40966061 | ||
| Prevention of relapse using granulocyte CSF-primed PBPCs following HLA-mismatched/haploidentical, T-cell-replete hematopoietic SCT in patients with advanced-stage acute leukemia: a retrospective risk-factor analysis | Q43690436 | ||
| Donor lymphocyte infusion and methotrexate for immune recovery after T-cell depleted haploidentical transplantation. | Q46390290 | ||
| Minimal/measurable residual disease in AML: consensus document from ELN MRD Working Party. | Q47734674 | ||
| Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Cente | Q52374880 | ||
| Donor lymphocyte infusion for the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoieti | Q53033981 | ||
| High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen. | Q53152680 | ||
| Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation. | Q53526081 | ||
| Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AML. | Q53776386 | ||
| Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: A report of 1578 patients from the Acute Leukemia Working Party of EBMT | Q58557066 | ||
| Analysis of Risk Factors for Outcomes After Unrelated Cord Blood Transplantation in Adults With Lymphoid Malignancies: A Study by the Eurocord-Netcord and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation | Q58865865 | ||
| Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the Acute Leukaemia Working Party of EBMT | Q64120846 | ||
| Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation | Q79879740 | ||
| Competing risk analysis using R: an easy guide for clinicians | Q80466908 | ||
| Prevention of relapse using DLI can increase survival following HLA-identical transplantation in patients with advanced-stage acute leukemia: a multi-center study | Q83929304 | ||
| Myeloablative T cell-depleted alloSCT with early sequential prophylactic donor lymphocyte infusion is an efficient and safe post-remission treatment for adult ALL | Q87233020 | ||
| Improved Outcome of Refractory/Relapsed Acute Myeloid Leukemia after Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation with Myeloablative Conditioning and Early Prophylactic Granulocyte Colony-Stimulating Factor-Mobilized Do | Q88018240 | ||
| P921 | main subject | acute leukemia | Q976388 |
| P577 | publication date | 2020-10-19 | |
| P1433 | published in | Bone Marrow Transplantation | Q4941523 |
| P1476 | title | Prophylactic modified donor lymphocyte infusion after low-dose ATG-F-based haploidentical HSCT with myeloablative conditioning in high-risk acute leukemia: a matched-pair analysis |
Search more.